Movano (MOVE) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 10, 2023
Document Information Line Items
Entity Registrant Name	MOVANO INC.
Trading Symbol	MOVE
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		50,805,951
Amendment Flag	false
Entity Central Index Key	0001734750
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-40254
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4233771
Entity Address, Address Line One	6800 Koll Center Parkway
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94566
City Area Code	(415)
Local Phone Number	651-3172
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 7,669	$ 10,759
Payroll tax credit, current portion	250	379
Vendor deposits	601	103
Prepaid expenses and other current assets	657	405
Total current assets	9,177	11,646
Property and equipment, net	363	443
Payroll tax credit, noncurrent portion	667	667
Other assets	386	487
Total assets	10,593	13,243
Current liabilities:
Accounts payable	1,955	557
Other current liabilities	3,578	4,421
Total current liabilities	5,533	4,978
Noncurrent liabilities:
Early exercised stock option liability	47	136
Other noncurrent liabilities	69	214
Total noncurrent liabilities	116	350
Total liabilities	5,649	5,328
Commitments and contingencies (Note 11)
Preferred stock, $0.0001 par value, 5,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.0001 par value, 150,000,000 shares authorized at September 30, 2023 and 75,000,000 at December 31, 2022; 50,805,951 and 33,659,460 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	5	3
Additional paid-in capital	123,361	103,009
Accumulated deficit	(118,422)	(95,097)
Total stockholders’ equity	4,944	7,915
Total liabilities and stockholders’ equity	$ 10,593	$ 13,243

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	75,000,000
Common stock, shares issued	50,805,951	33,659,460
Common stock, shares outstanding	50,805,951	33,659,460

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
OPERATING EXPENSES:
Research and development	$ 5,636	$ 5,146	$ 13,701	$ 13,849
Sales, general and administrative	3,443	3,511	9,965	8,592
Total operating expenses	9,079	8,657	23,666	22,441
Loss from operations	(9,079)	(8,657)	(23,666)	(22,441)
Other income (expense), net:
Interest and other income, net	117	55	341	39
Other income (expense), net	117	55	341	39
Net loss	(8,962)	(8,602)	(23,325)	(22,402)
Net loss	(8,962)	(8,602)	(23,325)	(22,402)
Other comprehensive income (loss):
Change in unrealized loss on available-for-sale securities		7		(3)
Total comprehensive loss	$ (8,962)	$ (8,595)	$ (23,325)	$ (22,405)
Net loss per share, basic (in Dollars per share)	$ (0.18)	$ (0.26)	$ (0.53)	$ (0.68)
Weighted average shares used in computing net loss per share, basic (in Shares)	50,711,449	32,949,649	43,818,011	32,829,940

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net loss per share, diluted	$ (0.18)	$ (0.26)	$ (0.53)	$ (0.68)
Weighted average shares used in computing net loss per share, diluted	50,711,449	32,949,649	43,818,011	32,829,940

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2021	$ 3	$ 97,506	$ (11)	$ (64,768)	$ 32,730
Balance (in Shares) at Dec. 31, 2021	32,772,060
Stock-based compensation		2,273			2,273
Issuance of common stock, net of issuance costs		1,921			1,921
Issuance of common stock, net of issuance costs (in Shares)	673,191
Issuance of common stock warrant
Issuance of common stock upon exercise of options		19			19
Issuance of common stock upon exercise of options (in Shares)	47,000
Vesting of early exercised stock options		110			110
Other comprehensive gain			6		6
Net loss				(22,402)	(22,402)
Balance at Sep. 30, 2022	$ 3	101,829	(5)	(87,170)	14,657
Balance (in Shares) at Sep. 30, 2022	33,492,251
Balance at Jun. 30, 2022	$ 3	99,077	(15)	(78,568)	20,497
Balance (in Shares) at Jun. 30, 2022	32,818,060
Stock-based compensation		797			797
Issuance of common stock, net of issuance costs		1,921			1,921
Issuance of common stock, net of issuance costs (in Shares)	673,191
Issuance of common stock upon exercise of options
Issuance of common stock upon exercise of options (in Shares)	1,000
Vesting of early exercised stock options		34			34
Other comprehensive gain			10		10
Net loss				(8,602)	(8,602)
Balance at Sep. 30, 2022	$ 3	101,829	(5)	(87,170)	14,657
Balance (in Shares) at Sep. 30, 2022	33,492,251
Balance at Dec. 31, 2022	$ 3	103,009		(95,097)	$ 7,915
Balance (in Shares) at Dec. 31, 2022	33,659,460				33,659,460
Stock-based compensation		2,252			$ 2,252
Issuance of common stock upon February 2023 public offering, net of issuance costs	$ 1	5,179			5,180
Issuance of common stock upon February 2023 public offering, net of issuance costs (in Shares)	5,340,600
Issuance of warrants upon February 2023 public offering		1,473			1,473
Issuance of common stock upon June 2023 public offering, net of issuance costs	$ 1	8,065			8,066
Issuance of common stock upon June 2023 public offering, net of issuance costs (in Shares)	9,200,000
Issuance of common stock, net of issuance costs		3,061			3,061
Issuance of common stock, net of issuance costs (in Shares)	2,360,036
Issuance of common stock warrant		124			124
Issuance of common stock upon exercise of options		109			109
Issuance of common stock upon exercise of options (in Shares)	245,855
Vesting of early exercised stock options		89			89
Net loss				(23,325)	(23,325)
Balance at Sep. 30, 2023	$ 5	123,361		(118,422)	$ 4,944
Balance (in Shares) at Sep. 30, 2023	50,805,951				50,805,951
Balance at Jun. 30, 2023	$ 5	122,283		(109,460)	$ 12,828
Balance (in Shares) at Jun. 30, 2023	50,646,661
Stock-based compensation		757			757
Issuance of common stock, net of issuance costs		173			173
Issuance of common stock, net of issuance costs (in Shares)	159,290
Vesting of early exercised stock options		24			24
Net loss				(8,962)	(8,962)
Balance at Sep. 30, 2023	$ 5	$ 123,361		$ (118,422)	$ 4,944
Balance (in Shares) at Sep. 30, 2023	50,805,951				50,805,951

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (23,325)	$ (22,402)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	118	109
Stock-based compensation	2,252	2,273
Noncash lease expense	(11)	(9)
Accretion of discount on short-term investments		101
Loss on disposal of property and equipment	13	44
Changes in operating assets and liabilities:
Payroll tax credit	129
Prepaid expenses, vendor deposits and other current assets	(626)	354
Other assets	(40)	(6)
Accounts payable	1,398	310
Other current and noncurrent liabilities	(836)	636
Net cash used in operating activities	(20,928)	(18,590)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(51)	(84)
Maturities of short-term investments		15,004
Net cash provided by (used in) investing activities	(51)	14,920
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock and warrants upon February 2023 public offering, net of issuance costs	6,653
Issuance of common stock upon June 2023 public offering, net of issuance costs	8,066
Issuance of common stock, net of issuance costs	3,061	1,921
Issuance of common stock upon exercise of stock options	109	19
Net cash provided by financing activities	17,889	1,940
Net decrease in cash and cash equivalents	(3,090)	(1,730)
Cash and cash equivalents at beginning of period	10,759	17,675
Cash and cash equivalents at end of period	7,669	15,945
NONCASH INVESTING AND FINANCING ACTIVITIES:
Vesting of common stock issued upon early exercise	89	110
Warrants issued upon February 2023 public offering	1,473
Issuance of common stock warrant	$ 124

Business Organization, Nature o

Business Organization, Nature of Operations	9 Months Ended
	Sep. 30, 2023
Business Organization, Nature of Operations [Abstract]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS	Note 1 – Business Organization, Nature of Operations Movano Inc., dba Movano Health (the “Company”, “Movano”, “Movano Health”, “we”, “us” or “our”) was incorporated in Delaware on January 30, 2018 as Maestro Sensors Inc. and changed its name to Movano Inc. on August 3, 2018. The Company is in the development-stage and is developing a platform to deliver purpose-driven healthcare solutions at the intersection of medical and consumer devices. Movano is on a mission to make medical grade data more accessible and actionable for all. The Company’s solutions are being developed to provide vital health information, including heart rate, heart rate variability (HRV), sleep, respiration rate, temperature, blood oxygen saturation (SpO 2 On April 28, 2021, the Company established Movano Ireland Limited, organized under the laws of Ireland, as a wholly owned subsidiary of the Company. Operations and activity at the wholly owned subsidiary were not significant for the nine months ended September 30, 2023 and 2022, respectively. Since inception, the Company has engaged in only limited research and development of product candidates and underlying technology and the commercialization of our first proposed commercial product, the Evie Ring. As of September 30, 2023, the Company had not yet completed its first product launch and had not yet recorded any revenues. On February 6, 2023, the Company completed a $7.5 million underwritten public offering of 5,340,600 shares of its common stock and warrants to purchase up to 2,670,300 shares of common stock, including the full exercise of the underwriter’s overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of $1.57. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock and accompanying warrant was $1.40. The net proceeds from the offering were approximately $6.7 million (See Note 8). On June 15, 2023, the Company completed a $9.2 million underwritten public offering of 9,200,000 shares of its common stock, including the full exercise of the underwriter’s overallotment option. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock was $1.00. The net proceeds from the offering were approximately $8.1 million (See Note 8). The Company has incurred losses from operations and has generated negative cash flows from operating activities since inception. The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Through September 30, 2023, the Company has relied primarily on the proceeds from equity offerings to finance its operations. The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products. The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans. Liquidity and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has an accumulated deficit of $118.4 million as of September 30, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. The Company’s existence is dependent upon management’s ability to obtain additional funding sources. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its product or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. Intercompany transactions are eliminated in the condensed consolidated financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the preceding fiscal year contained in the Company’s Annual Report on Form 10-K filed on March 30, 2023 with the United States Securities and Exchange Commission (the “SEC”). The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023. The condensed consolidated balance sheet as of December 31, 2022 has been derived from audited financial statements at that date but does not include all the information required by GAAP for complete financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the Chief Executive Officer. Cash, Cash Equivalents and Short-term Investments The Company invests its excess cash primarily in money market funds, commercial paper and short-term debt securities. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of September 30, 2023 and December 31, 2022, the Company did not hold any short-term investments. Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. Substantially all cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts. The amounts deposited in the money market accounts exceed federally insured limits. Further, the Company has amounts in excess of federally insured limits as of September 30, 2023 at one financial institution that totaled approximately $0.2 million. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials. The Company has no financial instruments with off-balance sheet risk of loss. Warrants Warrants are accounted for as either equity-classified or liability-classified instructions based on an assessment of the warrant’s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financing instruments and met the definition of a derivative or a liability and whether the warrants meet all the requirements for equity classification. The assessment, which requires the use of professional judgement, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. If the warrant does meet the characteristics of a liability or a derivative, the warrant is measured at fair value. The derivative liabilities are remeasured at each period end, on a recurring basis, to the estimated fair value with the changes in fair value reflected as current period income or loss until the warrant is exercised, extinguished, or expires. If the warrant does not meet the characteristics of a liability or a derivative, the warrant is classified as equity and recorded at its fair value on the date of issuance. The fair value is estimated using the Black-Scholes option pricing model or the Monte Carlo methodology which contain estimates and assumptions that require careful consideration and judgment. Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur. Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses. Leases The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition, and if the lease is classified as an operating lease or finance lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”). Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term. Lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. For leases which do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considers relevant banking rates and the Company’s costs incurred for underwriting discounts and financing costs in its previous equity financings. The ROU assets also include any lease payments made and exclude lease incentives. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately. Short-term leases of twelve months or less, if any. are expensed as incurred which approximates the straight-line basis due to the short-term nature of the leases. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the three and nine months ended September 30, 2023 and 2022. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) — Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being recognized separately from their host contracts. The pronouncement also revises the derivatives scope exception for contracts in an entity’s own equity and improves the consistency of earnings per share calculations as that relates to convertible instruments. The Company has early-adopted this pronouncement as of January 1, 2023 using the modified retrospective method of transition. The adoption did not have any impact on the Company’s condensed consolidated financials.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	Note 3 – FAIR VALUE MEASUREMENTS Financial assets and liabilities are recorded at fair value. The Company uses a three-level hierarchy, which prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those financial instruments. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The Company measures its cash equivalents at fair value. The Company classifies its cash equivalents within Level 1 or Level 2 because the Company values these investments using quoted market prices or alternative pricing sources and models utilizing market observable inputs. The fair value of the Company’s Level 1 financial assets is based on quoted market prices of the identical underlying security. The fair value of the Company’s Level 2 financial assets is based on inputs that are directly or indirectly observable in the market, including the readily-available pricing sources for the identical underlying security that may not be actively traded. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying amounts of prepaid expenses, payroll tax credit, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these instruments. The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands): Fair Value Measurements September 30, 2023 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 7,090 $ 7,090 $ — $ — Total cash equivalents $ 7,090 $ 7,090 $ — $ — December 31, 2022 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 8,171 $ 8,171 $ — $ — Total cash equivalents $ 8,171 $ 8,171 $ — $ —

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2023
Cash and Cash Equivalents [Abstract]
CASH AND CASH EQUIVALENTS	Note 4 – CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of the following (in thousands): September 30, December 31, 2023 2022 Cash and cash equivalents: Cash $ 579 $ 2,588 Money market funds 7,090 8,171 Total cash and cash equivalents $ 7,669 $ 10,759

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 5 – Property and Equipment Property and equipment, net, as of September 30, 2023 and December 31, 2022, consisted of the following (in thousands): September 30, December 31, 2023 2022 Office equipment and furniture $ 274 $ 263 Software 144 131 Test equipment 291 277 Total property and equipment 709 671 Less: accumulated depreciation (346 ) (228 ) Total property and equipment, net $ 363 $ 443 Total depreciation and amortization expense related to property and equipment for the three and nine months ended September 30, 2023 was approximately $40,000 and $118,000, respectively. Total depreciation and amortization expense related to property and equipment for the three and nine months ended September 30, 2022 was approximately $36,000 and $109,000, respectively.

Other Current Liabilities

Other Current Liabilities	9 Months Ended
	Sep. 30, 2023
Other Current Liabilities [Abstract]
OTHER CURRENT LIABILITIES	Note 6 – Other Current Liabilities Other current liabilities as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands): September 30, December 31, 2023 2022 Accrued compensation $ 1,809 $ 2,708 Accrued research and development 833 536 Accrued vacation 323 243 Accrued severance payment 61 517 Accrued sales and marketing 134 — Lease liabilities, current portion 204 212 Other 214 205 $ 3,578 $ 4,421

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2023
Redeemable Convertible Preferred Stock [Abstract]
REDEEMABLE CONVERTIBLE PREFERRED STOCK	Note 7 – REDEEMABLE Convertible Preferred Stock On March 24, 2021, the Company’s Third Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) eliminated the Company’s Series A and Series B preferred stock, (ii) increased the authorized number of shares of common stock to 75,000,000 and (iii) authorized 5,000,000 shares of preferred stock at par value of $0.0001 per share. The significant rights and preferences of the preferred stock will be established by the Company’s Board of Directors (the “Board”) upon issuance of any such series of preferred stock in the future. On June 21, 2023, the Company filed a Certificate of Amendment to its Third Amended and Restated Certificate of Incorporation with the Delaware Secretary of State which (i) increased the authorized number of shares of common stock to 150,000,000 and (ii) authorized 5,000,000 shares of preferred stock at a par value of $0.0001 per share, for a total of 155,000,000 authorized shares.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2023
Common Stock [Abstract]
COMMON STOCK	Note 8 – Common Stock As of September 30, 2023 and December 31, 2022, the Company was authorized to issue 150,000,000 and 75,000,000 shares of common stock, respectively, with a par value of $0.0001 per share. As of September 30, 2023 and December 31, 2022, 50,805,951 and 33,659,460 shares were outstanding, respectively. January and February 2023 Issuance of Common Stock On February 6, 2023, the Company completed a $7.5 million underwritten public offering of 5,340,600 shares of its common stock and warrants to purchase up to 2,670,300 shares of common stock, including the full exercise of the underwriter’s overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of $1.57 (See Note 9). The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock and accompanying warrant was $1.40. The Company used the relative fair value method to allocate the gross proceeds of approximately $7.5 million between the common stock and the warrants. The net proceeds from the offering were approximately $6.7 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately $0.8 million. The Company recorded the fair value of the warrants of $1.5 million as additional costs of issuance, thus reducing the net proceeds of $6.7 million to $5.2 million as presented in the accompanying condensed consolidated statements of stockholders’ equity. June 2023 Issuance of Common Stock On June 15, 2023, the Company completed a $9.2 million underwritten public offering of 9,200,000 shares of its common stock, including the full exercise of the underwriter’s overallotment option. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock and accompanying warrant was $1.00. The net proceeds from the offering were approximately $8.1 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately $1.1 million. At-the-Market Issuance of Common Stock On August 15, 2022, the Company entered into an At-the-Market Issuance Agreement (the “Issuance Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”). Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company’s common stock having an aggregate offering price of up to $50,000,000 (the “Shares”). Sales of Shares, if any, may be made by means of transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act, including block trades, ordinary brokers’ transactions on the Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices or by any other method permitted by law. Under the terms of the Issuance Agreement, the Company may also sell Shares to the Sales Agent as principal for its own accounts at a price to be agreed upon at the time of sale. Any sale of Shares to the Sales Agent as principal would be pursuant to the terms of a separate terms agreement between the Company and the Sales Agent. The Company has no obligation to sell any of the Shares under the Issuance Agreement and may at any time suspend solicitation and offers under the Issuance Agreement. During the nine months ended September 30, 2023, the Company issued and sold an aggregate of 2,360,036 shares of common stock through the Issuance Agreement at a weighted-average public offering price of $1.34 per share and received net proceeds of $3.1 million. As of September 30, 2023, an aggregate offering price amount of approximately $44.5 million remains available to be issued and sold under the Issuance Agreement. Common Stock Reserved for Future Issuance Common stock reserved for future issuance at September 30, 2023 is summarized as follows: September 30, 2023 Warrants to purchase common stock 4,757,256 Stock options outstanding 7,829,066 Stock options available for future grants 5,556,038 Total 18,142,360 Early Exercised Stock Option Liability During the three and nine months ended September 30, 2023 and 2022, no shares were issued upon the early exercise of common stock options. The Exercise Notice (Early Exercise) Agreement states that the Company has the option to repurchase all or a portion of the unvested shares in the event of the separation of the holder from service to the Company. The shares continue to vest in accordance with the original vesting schedules of the former option agreements. As of September 30, 2023 and December 31, 2022, the Company has recorded a repurchase liability for approximately $47,000

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2023
Common Stock Warrants [Abstract]
COMMON STOCK WARRANTS	Note 9 – Common Stock Warrants During February 2023, the Board approved the amendment of 293,042 Preferred A Placement Warrants to extend the maturity date by six months for each warrant and to remove the cashless exercise provision in the warrant agreements. The amended maturity dates for 234,197 and 58,845 Preferred A Placement Warrants were in September 2023 and October 2023, respectively. The Company assessed the accounting treatment of the warrant amendments and determined that the amendments are modifications for accounting purposes. The Company determined the modifications had an insignificant impact on the condensed consolidated financial statements. During March 2023, the Preferred A Lead Investor Warrants for 52,500 shares of common stock expired. During September 2023, the Board approved an additional amendment of 234,197 Preferred A Placement Warrants to extend the maturity date from September 2023 to October 2023 for each warrant. The Company assessed the accounting treatment of the warrant amendment and determined that the amendment is a modification for accounting purposes. The Company determined the modification had an insignificant impact on the condensed consolidated financial statements. January and February 2023 Warrants In connection with the sale of common stock during January and February 2023, the Company issued warrants to purchase shares of common stock to common stockholders and to the underwriter for 2,322,000 and 348,300 shares, respectively. The warrants are exercisable upon issuance at $1.57 per share and have a 5-year term. Beginning with the one-year anniversary of the issuance dates, the Company may redeem the outstanding warrants in whole or in part at $0.25 per warrant at any time after the date on which (i) the closing price of the Company’s common stock has equaled or exceeded $4.87 for ten consecutive trading days and (ii) the daily trading volume of the Company’s common stock has exceeded 100,000 shares on each of ten trading days. A minimum of thirty days prior written notice of redemption is required. August 2023 Warrants In August 2023, the Company issued warrants to purchase 201,613 shares of common stock to a third-party professional services firm. The following is a summary of the Company’s warrant activity for the nine months ended September 30, 2022: Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 293,042 — — — — 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 52,500 — — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 463,798 — — — — 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 171,830 — — — — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 956,973 — — — — 956,973 March 2026 1,938,143 — — — — 1,938,143 The following is a summary of the Company’s warrant activity for the nine months ended September 30, 2023: Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 293,042 — — — — 293,042 October 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 52,500 — — (52,500 ) — — March 2023 Preferred B Placement Warrants April 2019 $ 2.10 463,798 — — — — 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 171,830 — — — — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 956,973 — — — — 956,973 March 2026 January 2023 warrants January 2023 $ 1.57 — 2,322,000 — — — 2,322,000 January 2028 February 2023 warrants February 2023 $ 1.57 — 348,000 — — — 348,000 February 2028 August 2023 warrants August 2023 $ 1.24 — 201,613 — — — 201,613 August 2028 1,938,143 2,871,613 — (52,500 ) — 4,757,256 Warrants Classified as Equity All of the Company’s outstanding warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance. January and February 2023 Warrants The warrants are classified as an equity instrument because they are both indexed to the Company’s own stock and classified in stockholders’ equity. The fair value of the warrants was estimated using a Monte Carlo simulation approach. Subsequent changes in fair value are not recognized as long as the warrants continue to be classified in equity. The fair value at the issuance date was calculated utilizing the Monte Carlo univariate pricing model, which simulates a distribution of stock prices for Movano throughout the remaining performance period, based on certain assumptions of stock price behavior. The following major assumptions were used: (1) the stock price of the Company follows a geometric Brownian motion; (2) the daily stock price for the Company is simulated until the termination date using a volatility estimate based on term-match daily stock price returns of peer companies; and (3) the valuation is done under a risk-neutral framework using the term-matched zero-coupon risk-free interest rate. The major inputs were: Issuance Dividend yield 0 % Expected volatility 60.83 % Risk-free interest rate 3.54 % Expected life 5.0 years Valuation date common stock price $ 1.39 The fair value of the January and February 2023 warrants at the issuance date is approximately $1.5 million. August 2023 Warrants The warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance using the Black-Scholes option pricing model with the following assumptions. The fair value as determined at the issuance date is recorded as a debit to prepaid expenses and other current assets in the condensed consolidated balance sheet. The assumptions used to calculate the fair value at issuance are as follows for the warrants issued during the three months ended September 30, 2023. There were no warrants issued during the three months ended September 30, 2022. The major inputs were: Issuance Dividend yield 0 % Expected volatility 57.06 % Risk-free interest rate 4.42 % Expected life 5.0 years Valuation date common stock price $ 1.24 The fair value of August 2023 warrants at the issuance date is approximately $0.1 million.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	Note 10 – Stock-based Compensation 2019 Equity Incentive Plan Effective as of November 18, 2019, the Company adopted the 2019 Omnibus Incentive Plan (“2019 Plan”) administered by the Board. The 2019 Plan provides for the issuance of incentive stock options, non-statutory stock options, and restricted stock awards, for the purchase of up to a total of 4,000,000 shares of the Company’s common stock to employees, directors, and consultants and replaces the previous plan. The Board or a committee of the Board has the authority to determine the amount, type, and terms of each award. The options granted under the 2019 Plan generally have a contractual term of ten years and a vesting term of four years with a one-year cliff. The exercise price for options granted under the 2019 Plan must generally be at least equal to 100% of the fair value of the Company’s common stock at the date of grant, as determined by the Board. The incentive stock options granted under the 2019 Plan to 10% or greater stockholders must have an exercise price at least equal to 110% of the fair value of the Company’s common stock at the date of grant, as determined by the Board, and have a contractual term of ten years. Subsequent amendments to the 2019 Plan increased the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan to 13,400,000. As of September 30, 2023, the Company had 4,240,204 shares available for future grant pursuant to the 2019 Plan. 2021 Employment Inducement Plan On September 15, 2021 the Company’s Board adopted the Movano, Inc. 2021 Inducement Award Plan (the “Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (“Rule 5635(c)(4)”). In accordance with Rule 5635(c)(4), awards under the Inducement Plan may only be made to a newly hired employee who has not previously been a member of the Company’s Board, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee’s entering into employment with the Company or its subsidiary. An aggregate of 2,000,000 shares of the Company’s common stock have been reserved for issuance under the Inducement Plan. As of September 30, 2023, the Company had 1,315,834 shares available for future grant under the Inducement Plan. Stock Options Stock option activity for the nine months ended September 30, 2023 was as follows (in thousands, except share, per share, and remaining life data): Number of Weighted Weighted Intrinsic Outstanding at December 31, 2022 6,919,894 $ 2.34 8.2 years $ 2,034 Granted 1,535,375 $ 1.25 Exercised (245,855 ) $ 0.44 Cancelled (380,348 ) $ 3.21 Outstanding at September 30, 2023 7,829,066 $ 2.16 7.8 years $ 1,390 Exercisable as of September 30, 2023 4,968,590 $ 1.89 7.4 years $ 1,327 Vested and expected to vest as of September 30, 2023 7,778,866 $ 2.17 7.8 years $ 1,354 The weighted-average grant date fair value of options granted during the nine months ended September 30, 2023 and 2022, was $0.75 and $1.51, respectively. During the nine months ended September 30, 2023 and 2022, 245,855 and 47,000 options were exercised for proceeds of $109,000 and $19,000, respectively. The fair value of the 1,384,174 and 1,370,977 options that vested during the nine months ended September 30, 2023 and 2022 was approximately $2.2 million and $2.9 million, respectively. On June 21, 2022, the Company granted an award of 100,000 options to the Company’s founder at an exercise price of $5.00 per share. The options would have vested in full upon the shipment of 20,000 product units on or before June 30, 2023. For the nine months ended September 30, 2023, the Company has not recognized stock compensation expense of approximately $100,000 related to this award as the successful achievement of the performance condition was not probable, and the award has been cancelled. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of the stock options was estimated using the following weighted average assumptions for the nine months ended September 30, 2023 and 2022. Nine Months Ended 2023 2022 Dividend yield — % — % Expected volatility 61.88 % 61.91 % Risk-free interest rate 3.73 % 2.63 % Expected life 5.97 years 6.07 years Dividend Rate Expected Volatility Risk-Free Interest Rate Expected Term Forfeiture Rate The Company has recorded stock-based compensation expense for the three and nine months ended September 30, 2023 and 2022 related to the issuance of stock option awards to employees and nonemployees in the condensed consolidated statement of operations and comprehensive loss as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Research and development $ 228 $ 295 $ 678 $ 901 Sales, general and administrative 529 502 1,574 1,372 $ 757 $ 797 $ 2,252 $ 2,273 As of September 30, 2023, unamortized compensation expense related to unvested stock options (excluding the performance award previously described above) was approximately $5.3 million, which is expected to be recognized over a weighted average period of 2.2 years.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 11 – Commitments and Contingencies Operating Leases As of September 30, 2023, the Company had one office lease for the corporate headquarters and laboratory space. On April 15, 2021, the Company executed a lease agreement for corporate office space. The lease commenced on May 14, 2021 when the improvements were completed by the landlord and the Company had access to the facility. The lease term is 40 months, and the base rent is approximately $14,000 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid a security deposit of approximately $47,000. On April 22, 2022, the Company executed an amendment to its corporate office lease agreement for additional corporate office space. The lease term for the additional space is 36 months from the expansion commencement date of June 23, 2022. The base rent is approximately $5,100 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid an additional security deposit of approximately $5,500. The balances of the operating lease related accounts as of September 30, 2023 and December 31, 2022 are as follows (in thousands): Operating leases As of As of Right-of-use assets $ 248 $ 389 Operating lease liabilities - Short-term $ 204 $ 212 Operating lease liabilities - Long-term $ 69 $ 214 The components of lease expense and supplemental cash flow information as of and for the three and nine months ended September 30, 2023 and 2022 are as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Lease Cost: Operating lease cost $ 65 $ 69 $ 193 $ 163 Other Information: Cash paid for amounts included in the measurement of lease liabilities for the year ended $ 61 $ 59 $ 180 $ 149 Weighted average remaining lease term - operating leases (in years) 1.2 2.2 1.2 2.2 Average discount rate - operating lease 10.00 % 10.00 % 10.00 % 10.00 % Future minimum lease payments for the operating lease are as follows as of September 30, 2023 (in thousands): 2023 $ 61 2024 203 2025 28 Total lease payments 292 Less: Interest (19 ) Total operating lease liability $ 273 Litigation From time to time, the Company may become involved in various litigation and administrative proceedings relating to claims arising from its operations in the normal course of business. Management is not currently aware of any matters that may have a material adverse impact on the Company’s business, financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. No amounts associated with such indemnifications have been recorded as of September 30, 2023. Non-cancelable Obligations The Company also had approximately $10,000 of non-cancelable contractual commitments as of September 30, 2023, primarily related to its vendor arrangements. These commitments are generally due within one to three months.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2023
Net Loss Per Share [Abstract]
NET LOSS PER SHARE	Note 12 – NET LOSS PER SHARE The following table provides the computation of the basic and diluted net loss per share during the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net loss $ (8,962 ) $ (8,602 ) $ (23,325 ) $ (22,402 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 50,711,449 32,949,649 43,818,011 32,829,940 Net loss per share, basic and diluted $ (0.18 ) $ (0.26 ) $ (0.53 ) $ (0.68 ) The potential shares of common stock that were excluded from the computation of diluted net loss per share for the nine months ended September 30, 2023 and 2022 because including them would have been antidilutive are as follows: Nine Months Ended 2023 2022 Shares subject to options to purchase common stock 7,778,866 7,834,771 Shares subject to warrants to purchase common stock 4,757,256 1,938,143 Total 12,536,122 9,772,914 For the three and nine months ended September 30, 2023, performance-based option awards for 50,200 shares of common stock are not included in the table above or considered in the calculation of diluted earnings per share because the performance conditions of the option award are not considered probable by the Company. For the three and nine months ended September 30, 2022, performance-based option awards for 150,200 shares of common stock are not included in the table above or considered in the calculation of diluted earnings per share because the performance conditions of the option award are not considered probable by the Company.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 13 – SUBSEQUENT EVENTS During November 2023, the Board authorized the Company to undertake a public offering of the Company’s common stock in a firm commitment underwritten public offering up to the amount available under the Company’s shelf registration statement in common stock with the number of shares of common stock to be sold, the price at which such shares are sold and other terms to be determined by the designated and authorized pricing committee.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. Intercompany transactions are eliminated in the condensed consolidated financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the preceding fiscal year contained in the Company’s Annual Report on Form 10-K filed on March 30, 2023 with the United States Securities and Exchange Commission (the “SEC”). The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023. The condensed consolidated balance sheet as of December 31, 2022 has been derived from audited financial statements at that date but does not include all the information required by GAAP for complete financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the Chief Executive Officer.
Cash, Cash Equivalents and Short-term Investments	Cash, Cash Equivalents and Short-term Investments The Company invests its excess cash primarily in money market funds, commercial paper and short-term debt securities. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of September 30, 2023 and December 31, 2022, the Company did not hold any short-term investments.
Concentrations of Credit Risk and Off-Balance Sheet Risk	Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. Substantially all cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts. The amounts deposited in the money market accounts exceed federally insured limits. Further, the Company has amounts in excess of federally insured limits as of September 30, 2023 at one financial institution that totaled approximately $0.2 million. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials. The Company has no financial instruments with off-balance sheet risk of loss.
Warrants	Warrants Warrants are accounted for as either equity-classified or liability-classified instructions based on an assessment of the warrant’s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financing instruments and met the definition of a derivative or a liability and whether the warrants meet all the requirements for equity classification. The assessment, which requires the use of professional judgement, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. If the warrant does meet the characteristics of a liability or a derivative, the warrant is measured at fair value. The derivative liabilities are remeasured at each period end, on a recurring basis, to the estimated fair value with the changes in fair value reflected as current period income or loss until the warrant is exercised, extinguished, or expires. If the warrant does not meet the characteristics of a liability or a derivative, the warrant is classified as equity and recorded at its fair value on the date of issuance. The fair value is estimated using the Black-Scholes option pricing model or the Monte Carlo methodology which contain estimates and assumptions that require careful consideration and judgment.
Stock-Based Compensation	Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur.
Early Exercised Stock Option Liability	Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses.
Leases	Leases The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition, and if the lease is classified as an operating lease or finance lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”). Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term. Lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. For leases which do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considers relevant banking rates and the Company’s costs incurred for underwriting discounts and financing costs in its previous equity financings. The ROU assets also include any lease payments made and exclude lease incentives. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately. Short-term leases of twelve months or less, if any. are expensed as incurred which approximates the straight-line basis due to the short-term nature of the leases.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the three and nine months ended September 30, 2023 and 2022. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) — Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being recognized separately from their host contracts. The pronouncement also revises the derivatives scope exception for contracts in an entity’s own equity and improves the consistency of earnings per share calculations as that relates to convertible instruments. The Company has early-adopted this pronouncement as of January 1, 2023 using the modified retrospective method of transition. The adoption did not have any impact on the Company’s condensed consolidated financials.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Measurements [Abstract]
Schedule of Assets and Liabilities that are Measured at Fair Value	The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands): September 30, 2023 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 7,090 $ 7,090 $ — $ — Total cash equivalents $ 7,090 $ 7,090 $ — $ — December 31, 2022 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 8,171 $ 8,171 $ — $ — Total cash equivalents $ 8,171 $ 8,171 $ — $ —

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Sep. 30, 2023
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents consist of the following (in thousands): September 30, December 31, 2023 2022 Cash and cash equivalents: Cash $ 579 $ 2,588 Money market funds 7,090 8,171 Total cash and cash equivalents $ 7,669 $ 10,759

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net, as of September 30, 2023 and December 31, 2022, consisted of the following (in thousands): September 30, December 31, 2023 2022 Office equipment and furniture $ 274 $ 263 Software 144 131 Test equipment 291 277 Total property and equipment 709 671 Less: accumulated depreciation (346 ) (228 ) Total property and equipment, net $ 363 $ 443

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Other Current Liabilities [Abstract]
Schedule of Other Current Liabilities	Other current liabilities as of September 30, 2023 and December 31, 2022 consisted of the following (in thousands): September 30, December 31, 2023 2022 Accrued compensation $ 1,809 $ 2,708 Accrued research and development 833 536 Accrued vacation 323 243 Accrued severance payment 61 517 Accrued sales and marketing 134 — Lease liabilities, current portion 204 212 Other 214 205 $ 3,578 $ 4,421

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2023
Common Stock [Abstract]
Schedule of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance at September 30, 2023 is summarized as follows: September 30, 2023 Warrants to purchase common stock 4,757,256 Stock options outstanding 7,829,066 Stock options available for future grants 5,556,038 Total 18,142,360

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2023
Common Stock Warrants [Abstract]
Schedule of Company's Warrant Activity	The following is a summary of the Company’s warrant activity for the nine months ended September 30, 2022: Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 293,042 — — — — 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 52,500 — — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 463,798 — — — — 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 171,830 — — — — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 956,973 — — — — 956,973 March 2026 1,938,143 — — — — 1,938,143 Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 293,042 — — — — 293,042 October 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 52,500 — — (52,500 ) — — March 2023 Preferred B Placement Warrants April 2019 $ 2.10 463,798 — — — — 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 171,830 — — — — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 956,973 — — — — 956,973 March 2026 January 2023 warrants January 2023 $ 1.57 — 2,322,000 — — — 2,322,000 January 2028 February 2023 warrants February 2023 $ 1.57 — 348,000 — — — 348,000 February 2028 August 2023 warrants August 2023 $ 1.24 — 201,613 — — — 201,613 August 2028 1,938,143 2,871,613 — (52,500 ) — 4,757,256
Schedule of Major Inputs	The major inputs were: Issuance Dividend yield 0 % Expected volatility 60.83 % Risk-free interest rate 3.54 % Expected life 5.0 years Valuation date common stock price $ 1.39 Issuance Dividend yield 0 % Expected volatility 57.06 % Risk-free interest rate 4.42 % Expected life 5.0 years Valuation date common stock price $ 1.24

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Stock-Based Compensation [Abstract]
Schedule of Stock Option Activity	Stock option activity for the nine months ended September 30, 2023 was as follows (in thousands, except share, per share, and remaining life data): Number of Weighted Weighted Intrinsic Outstanding at December 31, 2022 6,919,894 $ 2.34 8.2 years $ 2,034 Granted 1,535,375 $ 1.25 Exercised (245,855 ) $ 0.44 Cancelled (380,348 ) $ 3.21 Outstanding at September 30, 2023 7,829,066 $ 2.16 7.8 years $ 1,390 Exercisable as of September 30, 2023 4,968,590 $ 1.89 7.4 years $ 1,327 Vested and expected to vest as of September 30, 2023 7,778,866 $ 2.17 7.8 years $ 1,354
Schedule of Weighted Average Assumptions for Fair Value of Options Estimated	The fair value of the stock options was estimated using the following weighted average assumptions for the nine months ended September 30, 2023 and 2022. Nine Months Ended 2023 2022 Dividend yield — % — % Expected volatility 61.88 % 61.91 % Risk-free interest rate 3.73 % 2.63 % Expected life 5.97 years 6.07 years
Schedule of Stock-Based Compensation Expense to Employees and Non-Employees	The Company has recorded stock-based compensation expense for the three and nine months ended September 30, 2023 and 2022 related to the issuance of stock option awards to employees and nonemployees in the condensed consolidated statement of operations and comprehensive loss as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Research and development $ 228 $ 295 $ 678 $ 901 Sales, general and administrative 529 502 1,574 1,372 $ 757 $ 797 $ 2,252 $ 2,273

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies [Abstract]
Schedule of Components of Lease Expense and Supplemental Cash Flow Information	The balances of the operating lease related accounts as of September 30, 2023 and December 31, 2022 are as follows (in thousands): Operating leases As of As of Right-of-use assets $ 248 $ 389 Operating lease liabilities - Short-term $ 204 $ 212 Operating lease liabilities - Long-term $ 69 $ 214 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Lease Cost: Operating lease cost $ 65 $ 69 $ 193 $ 163 Other Information: Cash paid for amounts included in the measurement of lease liabilities for the year ended $ 61 $ 59 $ 180 $ 149 Weighted average remaining lease term - operating leases (in years) 1.2 2.2 1.2 2.2 Average discount rate - operating lease 10.00 % 10.00 % 10.00 % 10.00 %
Schedule of Future Minimum Lease Payments	Future minimum lease payments for the operating lease are as follows as of September 30, 2023 (in thousands): 2023 $ 61 2024 203 2025 28 Total lease payments 292 Less: Interest (19 ) Total operating lease liability $ 273

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Net Loss Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table provides the computation of the basic and diluted net loss per share during the three and nine months ended September 30, 2023 and 2022 (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net loss $ (8,962 ) $ (8,602 ) $ (23,325 ) $ (22,402 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 50,711,449 32,949,649 43,818,011 32,829,940 Net loss per share, basic and diluted $ (0.18 ) $ (0.26 ) $ (0.53 ) $ (0.68 )
Schedule of Diluted Net Loss Per Share	The potential shares of common stock that were excluded from the computation of diluted net loss per share for the nine months ended September 30, 2023 and 2022 because including them would have been antidilutive are as follows: Nine Months Ended 2023 2022 Shares subject to options to purchase common stock 7,778,866 7,834,771 Shares subject to warrants to purchase common stock 4,757,256 1,938,143 Total 12,536,122 9,772,914

Business Organization, Nature_2

Business Organization, Nature of Operations (Details) - USD ($)			1 Months Ended	9 Months Ended
	Feb. 06, 2023	Feb. 06, 2023	Jun. 15, 2023	Sep. 30, 2023	Aug. 31, 2023
Business Organization, Nature of Operations (Details) [Line Items]
Underwritten public offering	$ 7,500,000	$ 7,500,000
Shares of common stock (in Shares)		5,340,600
Exercisable price per share (in Dollars per share)	$ 1.57	$ 1.57
Warrant per share (in Dollars per share)	$ 1.4
Net proceeds	$ 6,700,000		$ 8,100,000	$ 3,100,000
Share issued (in Shares)			9,200,000		201,613
Underwriter exercise			$ 9,200,000
Accumulated deficit				$ 118,400,000
Ability to continue going concern				1 year
Warrants [Member]
Business Organization, Nature of Operations (Details) [Line Items]
Shares of common stock (in Shares)		2,670,300
Common Stock [Member]
Business Organization, Nature of Operations (Details) [Line Items]
Exercisable at a price per share (in Dollars per share)			$ 1

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Accounting Policies [Abstract]
Number of segments	1
Amounts excess	$ 0.2

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of Assets and Liabilities that are Measured at Fair Value - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Cash equivalents:
Total cash equivalents	$ 7,090	$ 8,171
Money Market Funds [Member]
Cash equivalents:
Total cash equivalents	7,090	8,171
Level 1 [Member]
Cash equivalents:
Total cash equivalents	7,090	8,171
Level 1 [Member] | Money Market Funds [Member]
Cash equivalents:
Total cash equivalents	7,090	8,171
Level 2 [Member]
Cash equivalents:
Total cash equivalents
Level 2 [Member] | Money Market Funds [Member]
Cash equivalents:
Total cash equivalents
Level 3 [Member]
Cash equivalents:
Total cash equivalents
Level 3 [Member] | Money Market Funds [Member]
Cash equivalents:
Total cash equivalents

Cash and Cash Equivalents (Det

Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Cash and cash equivalents:
Total cash and cash equivalents	$ 7,669	$ 10,759
Cash [Member]
Cash and cash equivalents:
Total cash and cash equivalents	579	2,588
Money market funds [Member]
Cash and cash equivalents:
Total cash and cash equivalents	$ 7,090	$ 8,171

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property and Equipment [Abstract]
Total depreciation and amortization expense	$ 40,000	$ 36,000	$ 118,000	$ 109,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 709	$ 671
Less: accumulated depreciation	(346)	(228)
Total property and equipment, net	363	443
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	274	263
Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	144	131
Test equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 291	$ 277

Other Current Liabilities (Deta

Other Current Liabilities (Details) - Schedule of Other Current Liabilities - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Schedule of Other Current Liabilities [Abstract]
Accrued compensation	$ 1,809	$ 2,708
Accrued research and development	833	536
Accrued vacation	323	243
Accrued severance payment	61	517
Accrued sales and marketing	134
Lease liabilities, current portion	204	212
Other	214	205
Total other current liabilities	$ 3,578	$ 4,421

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Details) - $ / shares	Sep. 30, 2023	Jun. 21, 2023	Dec. 31, 2022	Mar. 24, 2021
Redeemable Convertible Preferred Stock (Details) [Line Items]
Common stock, shares authorized	150,000,000		75,000,000
Preferred stock, shares authorized	5,000,000	155,000,000	5,000,000
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Common stock, shares authorized		150,000,000
Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Preferred stock, shares authorized		5,000,000
Redeemable Convertible Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Common stock, shares authorized				75,000,000
Preferred stock, shares authorized				5,000,000
Preferred stock, par value (in Dollars per share)				$ 0.0001

Common Stock (Details)

Common Stock (Details) - USD ($)			1 Months Ended	9 Months Ended	12 Months Ended
	Feb. 06, 2023	Aug. 15, 2022	Jun. 15, 2023	Sep. 30, 2023	Dec. 31, 2022
Common Stock (Details) [Line Items]
Common stock, par value (in Dollars per share)				$ 0.0001	$ 0.0001
Common stock, shares outstanding (in Shares)				50,805,951	33,659,460
Underwritten public offering	$ 7,500,000
Common stock, shares issued (in Shares)	5,340,600			50,805,951	33,659,460
Exercisable price per share (in Dollars per share)	$ 1.57
Gross proceeds	$ 7,500,000
Net proceeds	6,700,000		$ 8,100,000	$ 3,100,000
Other offering expenses	800,000
Fair value of the warrants additional costs	1,500,000
Underwritten public offering			9,200,000
Other offering cost			$ 1,100,000
Aggregate offering price		$ 50,000,000		$ 44,500,000
Aggregate shares of common stock (in Shares)				2,360,036
Stock option, exercise price (in Dollars per share)				$ 1.34
Repurchase liability					$ 136,000
Shares unvested (in Shares)				87,501	266,147
Weighted average vesting period				1 year
Overallotment Option [Member]
Common Stock (Details) [Line Items]
Common stock, shares issued (in Shares)			9,200,000
Common Stock [Member]
Common Stock (Details) [Line Items]
Common stock, shares authorized (in Shares)				150,000,000	75,000,000
Maximum [Member]
Common Stock (Details) [Line Items]
Net proceeds	6,700,000
Minimum [Member]
Common Stock (Details) [Line Items]
Net proceeds	$ 5,200,000
Warrant [Member]
Common Stock (Details) [Line Items]
Common stock, shares issued (in Shares)	2,670,300
Warrants price (in Dollars per share)	$ 1.4		$ 1

Common Stock (Details) - Schedu

Common Stock (Details) - Schedule of Common Stock Reserved for Future Issuance	Sep. 30, 2023 shares
Schedule of Common Stock Reserved for Future Issuance [Abstract]
Warrants to purchase common stock	4,757,256
Stock options outstanding	7,829,066
Stock options available for future grants	5,556,038
Total	18,142,360

Common Stock Warrants (Details)

Common Stock Warrants (Details) - USD ($)				1 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 06, 2023	Jan. 31, 2023	Aug. 31, 2023	Feb. 28, 2023	Sep. 30, 2023	Jun. 15, 2023	Mar. 31, 2023
Common Stock Warrants (Details) [Line Items]
Board approved amendment, description						During February 2023, the Board approved the amendment of 293,042 Preferred A Placement Warrants to extend the maturity date by six months for each warrant and to remove the cashless exercise provision in the warrant agreements. The amended maturity dates for 234,197 and 58,845 Preferred A Placement Warrants were in September 2023 and October 2023, respectively.
Common stock expired								52,500
Placement warrant (in Dollars)						$ 234,197
Outstanding price per warrants (in Dollars per share)						$ 0.25
Exceeded price per share (in Dollars per share)		$ 1.4
Common stock shares				201,613			9,200,000
Warrants issuance (in Dollars)	$ 1,500,000		$ 1,500,000	$ 100,000
Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Underwriter shares			2,322,000		348,300
Warrant exercisable price per share (in Dollars per share)						$ 1.57
Warrants term						5 years
Common Stock [Member]
Common Stock Warrants (Details) [Line Items]
Exceeded price per share (in Dollars per share)						$ 4.87
Common stock exceeded shares						100,000

Common Stock Warrants (Detail_2

Common Stock Warrants (Details) - Schedule of Company's Warrant Activity - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Class of Warrant or Right [Line Items]
Warrant Issuance, Outstanding beginning	1,938,143	1,938,143
Warrant Issuance, Granted	2,871,613
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired	(52,500)
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	4,757,256	1,938,143
Preferred A Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	March and April 2018 and August 2019	March and April 2018 and August 2019
Warrant Issuance, Exercise Price (in Dollars per share)	$ 1.4	$ 1.4
Warrant Issuance, Outstanding beginning	293,042	293,042
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	293,042	293,042
Warrant Issuance, Expiration	October 2023	March and April 2023
Preferred A Lead Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	February 2021	February 2021
Warrant Issuance, Exercise Price (in Dollars per share)	$ 0.0125	$ 0.0125
Warrant Issuance, Outstanding beginning	52,500	52,500
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired	(52,500)
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending		52,500
Warrant Issuance, Expiration	March 2023	March 2023
Preferred B Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	April 2019	April 2019
Warrant Issuance, Exercise Price (in Dollars per share)	$ 2.1	$ 2.1
Warrant Issuance, Outstanding beginning	463,798	463,798
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	463,798	463,798
Warrant Issuance, Expiration	April 2024	April 2024
Convertible Notes Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	August 2020	August 2020
Warrant Issuance, Exercise Price (in Dollars per share)	$ 2.57	$ 2.57
Warrant Issuance, Outstanding beginning	171,830	171,830
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	171,830	171,830
Warrant Issuance, Expiration	August 2025	August 2025
Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	March 2021	March 2021
Warrant Issuance, Exercise Price (in Dollars per share)	$ 6	$ 6
Warrant Issuance, Outstanding beginning	956,973	956,973
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	956,973	956,973
Warrant Issuance, Expiration	March 2026	March 2026
January 2023 warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	January 2023
Warrant Issuance, Exercise Price (in Dollars per share)	$ 1.57
Warrant Issuance, Outstanding beginning
Warrant Issuance, Granted	2,322,000
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	2,322,000
Warrant Issuance, Expiration	January 2028
February 2023 warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	February 2023
Warrant Issuance, Exercise Price (in Dollars per share)	$ 1.57
Warrant Issuance, Outstanding beginning
Warrant Issuance, Granted	348,000
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	348,000
Warrant Issuance, Expiration	February 2028
August 2023 warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	August 2023
Warrant Issuance, Exercise Price (in Dollars per share)	$ 1.24
Warrant Issuance, Outstanding beginning
Warrant Issuance, Granted	201,613
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	201,613
Warrant Issuance, Expiration	August 2028

Common Stock Warrants (Detail_3

Common Stock Warrants (Details) - Schedule of Major Inputs - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Schedule of Major Inputs [Abstract]
Dividend yield	0%	0%
Expected volatility	60.83%	57.06%
Risk-free interest rate	3.54%	4.42%
Expected life	5 years	5 years
Valuation date common stock price (in Dollars per share)	$ 1.39	$ 1.24

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	1 Months Ended			9 Months Ended
	Jun. 21, 2022 $ / shares shares	Sep. 15, 2021 shares	Nov. 18, 2019 shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares
Stock-Based Compensation (Details) [Line Items]
Purchase price				2,360,036
Future grant shares				18,142,360
Stock option exercised, shares				245,855	47,000
Stock options exercised (in Dollars) | $				$ 109,000
Fair value option shares				1,384,174	1,370,977
Options vested (in Dollars) | $				$ 2,200,000	$ 2,900,000
Granted shares	100,000
Product units	20,000
Stock compensation expense (in Dollars) | $				100,000
Unamortized compensation expense (in Dollars) | $				$ 5,300,000
Weighted average period				2 years 2 months 12 days
Founder [Member]
Stock-Based Compensation (Details) [Line Items]
Exercise price per share (in Dollars per share) | $ / shares	$ 5
2019 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Purchase price			4,000,000
Contractual term			10 years
Vesting term			4 years
Exercise price percentage			10%
Aggregate shares issued			13,400,000
Future grant shares				4,240,204
2021 Employment Inducement Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued		2,000,000
Future grant shares				1,315,834
Minimum [Member] | 2019 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value percentage			100%
Maximum [Member] | 2019 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value percentage			110%
Stock Options [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value per share (in Dollars per share) | $ / shares				$ 0.75	$ 1.51
Stock options exercised (in Dollars) | $					$ 19,000

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Stock Option Activity - Stock Option [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Stock-Based Compensation (Details) - Schedule of Stock Option Activity [Line Items]
Number of Options, Outstanding Beginning | shares	6,919,894
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 2.34
Weighted Average Remaining Life, Outstanding Beginning	8 years 2 months 12 days
Intrinsic Value, Outstanding Beginning | $	$ 2,034
Number of Options, Outstanding Ending | shares	7,829,066
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 2.16
Weighted Average Remaining Life, Outstanding Ending	7 years 9 months 18 days
Intrinsic Value, Outstanding Ending | $	$ 1,390
Number of Options, Outstanding Exercisable | shares	4,968,590
Weighted Average Exercise Price, Outstanding Exercisable | $ / shares	$ 1.89
Weighted Average Remaining Life, Outstanding Exercisable	7 years 4 months 24 days
Intrinsic Value, Outstanding Exercisable | $	$ 1,327
Number of Options, Outstanding Vested and expected to vest | shares	7,778,866
Weighted Average Exercise Price, Outstanding Vested and expected to vest | $ / shares	$ 2.17
Weighted Average Remaining Life, Outstanding Vested and expected to vest	7 years 9 months 18 days
Intrinsic Value, Outstanding Vested and expected to vest | $	$ 1,354
Number of Options, Outstanding Granted | shares	1,535,375
Weighted Average Exercise Price, Outstanding Granted | $ / shares	$ 1.25
Number of Options, Outstanding Exercised | shares	(245,855)
Weighted Average Exercise Price, Outstanding Exercised | $ / shares	$ 0.44
Number of Options, Outstanding Cancelled | shares	(380,348)
Weighted Average Exercise Price, Outstanding Cancelled | $ / shares	$ 3.21

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Weighted Average Assumptions for Fair Value of Options Estimated - Black Scholes Fair Value Assumptions [Member]	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Stock-Based Compensation (Details) - Schedule of Weighted Average Assumptions for Fair Value of Options Estimated [Line Items]
Dividend yield
Expected volatility	61.88%	61.91%
Risk-free interest rate	3.73%	2.63%
Expected life	5 years 11 months 19 days	6 years 25 days

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense to Employees and Non-Employees - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense to Employees and Non-Employees [Line Items]
Total stock-based compensation	$ 757	$ 797	$ 2,252	$ 2,273
Research and development [Member]
Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense to Employees and Non-Employees [Line Items]
Total stock-based compensation	228	295	678	901
Sales, general and administrative [Member]
Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense to Employees and Non-Employees [Line Items]
Total stock-based compensation	$ 529	$ 502	$ 1,574	$ 1,372

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	1 Months Ended		9 Months Ended
	Apr. 22, 2022	Apr. 15, 2021	Sep. 30, 2023
Commitments and Contingencies [Abstract]
lease term	36 months	40 months
Base rent	$ 5,100	$ 14,000
Security deposit	$ 5,500	$ 47,000
Non-cancelable contractual commitments			$ 10,000

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Components of Lease Expense and Supplemental Cash Flow Information - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Schedule of Components of Lease Expense and Supplemental Cash Flow Information [Abstract]
Right-of-use assets	$ 248		$ 248		$ 389
Operating lease liabilities - Short-term	204		204		212
Operating lease liabilities - Long-term	69		69		$ 214
Lease Cost:
Operating lease cost	65	$ 69	193	$ 163
Other Information:
Cash paid for amounts included in the measurement of lease liabilities for the year ended	$ 61	$ 59	$ 180	$ 149
Weighted average remaining lease term - operating leases (in years)	1 year 2 months 12 days	2 years 2 months 12 days	1 year 2 months 12 days	2 years 2 months 12 days
Average discount rate - operating lease	10%	10%	10%	10%

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of Future Minimum Lease Payments $ in Thousands	Sep. 30, 2023 USD ($)
Schedule of Future Minimum Lease Payments [Abstract]
2023	$ 61
2024	203
2025	28
Total lease payments	292
Less: Interest	(19)
Total operating lease liability	$ 273

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Performance-Based Option Awards [Member]
Net Loss Per Share (Details) [Line Items]
Performance based option shares	50,200	150,200	50,200	150,200

Net Loss Per Share (Details) -

Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net loss	$ (8,962)	$ (8,602)	$ (23,325)	$ (22,402)
Denominator:
Weighted average shares used in computing net loss per share, basic	50,711,449	32,949,649	43,818,011	32,829,940
Net loss per share, basic	$ (0.18)	$ (0.26)	$ (0.53)	$ (0.68)

Net Loss Per Share (Details) _2

Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Basic and Diluted Net Loss Per Share [Abstract]
Weighted average shares used in computing net loss per share, diluted	50,711,449	32,949,649	43,818,011	32,829,940
Net loss per share,diluted	$ (0.18)	$ (0.26)	$ (0.53)	$ (0.68)

Net Loss Per Share (Details) _3

Net Loss Per Share (Details) - Schedule of Diluted Net Loss Per Share - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Schedule of Diluted Net Loss Per Share [Abstract]
Shares subject to options to purchase common stock	7,778,866	7,834,771
Shares subject to warrants to purchase common stock	4,757,256	1,938,143
Total	12,536,122	9,772,914